Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults

BACKGROUND: AZD7442 is a combination of extended half-life, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)−specific neutralizing monoclonal antibodies (tixagevimab and cilgavimab). METHODS: This phase 1, first-in-human, randomized, double-blind, placebo-controlled, dose-escalation stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Forte-Soto, Pablo, Albayaty, Muna, Brooks, Dennis, Arends, Rosalinda H, Tillinghast, John, Aksyuk, Anastasia A, Bouquet, Jerome, Chen, Cecil, Gebre, Asfiha, Kubiak, Robert J, Pilla Reddy, Venkatesh, Seegobin, Seth, Streicher, Katie, Templeton, Alison, Esser, Mark T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175065/
https://www.ncbi.nlm.nih.gov/pubmed/36683419
http://dx.doi.org/10.1093/infdis/jiad014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175065/
https://www.ncbi.nlm.nih.gov/pubmed/36683419
http://dx.doi.org/10.1093/infdis/jiad014

Ejemplares similares